Ftse Mib
34.490,71
0,07%
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
69.218,70
-0,07%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ TCR2 Therapeutics Inc (TCRR) TCR2 Therapeutics Inc (TCRR) Notizie

TCRR

TCR2 Therapeutics (TCRR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TCRR
DataOraFonteTitoloSimboloCompagnia
12/06/202313:01Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:TCRRTCR2 Therapeutics Inc
06/06/202312:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:TCRRTCR2 Therapeutics Inc
05/06/202322:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TCRRTCR2 Therapeutics Inc
01/06/202322:46Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:TCRRTCR2 Therapeutics Inc
01/06/202322:42Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:TCRRTCR2 Therapeutics Inc
01/06/202322:11Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRRTCR2 Therapeutics Inc
01/06/202315:35Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:TCRRTCR2 Therapeutics Inc
30/05/202322:22Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:TCRRTCR2 Therapeutics Inc
24/05/202322:57Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TCRRTCR2 Therapeutics Inc
11/05/202313:17Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TCRRTCR2 Therapeutics Inc
11/05/202312:30GlobeNewswire Inc.TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:TCRRTCR2 Therapeutics Inc
08/05/202322:05GlobeNewswire Inc.TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TCRRTCR2 Therapeutics Inc
06/05/202300:50Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:TCRRTCR2 Therapeutics Inc
05/05/202322:38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TCRRTCR2 Therapeutics Inc
20/04/202322:51Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:TCRRTCR2 Therapeutics Inc
23/03/202312:52Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:TCRRTCR2 Therapeutics Inc
23/03/202312:17Edgar (US Regulatory)Annual Report (10-k)NASDAQ:TCRRTCR2 Therapeutics Inc
23/03/202311:30GlobeNewswire Inc.TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:TCRRTCR2 Therapeutics Inc
06/03/202312:00GlobeNewswire Inc.Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsNASDAQ:TCRRTCR2 Therapeutics Inc
08/02/202312:45GlobeNewswire Inc.TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023NASDAQ:TCRRTCR2 Therapeutics Inc
05/01/202322:15GlobeNewswire Inc.TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TCRRTCR2 Therapeutics Inc
05/01/202314:45GlobeNewswire Inc.TCR² Therapeutics Announces Pipeline Priorities for 2023NASDAQ:TCRRTCR2 Therapeutics Inc
23/11/202212:45GlobeNewswire Inc.TCR² Therapeutics to Present at the Piper Sandler Healthcare ConferenceNASDAQ:TCRRTCR2 Therapeutics Inc
18/11/202222:08Edgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:TCRRTCR2 Therapeutics Inc
09/11/202209:25TipRanksMizuho Securities Sticks to Their Buy Rating for TCR2 Therapeutics (TCRR)NASDAQ:TCRRTCR2 Therapeutics Inc
08/11/202217:36TipRanksSVB Securities Keeps Their Hold Rating on TCR2 Therapeutics (TCRR)NASDAQ:TCRRTCR2 Therapeutics Inc
08/11/202212:45GlobeNewswire Inc.TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:TCRRTCR2 Therapeutics Inc
07/11/202214:01GlobeNewswire Inc.TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of CancerNASDAQ:TCRRTCR2 Therapeutics Inc
19/10/202222:16Edgar (US Regulatory)Tender Offer Statement by Issuer (sc To-i)NASDAQ:TCRRTCR2 Therapeutics Inc
29/09/202212:25TipRanksTCR2 Therapeutics (TCRR) Gets a Buy from H.C. WainwrightNASDAQ:TCRRTCR2 Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TCRR

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
TIT
Telecom Italia
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TEN
Tenaris
BIT
RACE
Ferrari NV
BIT
SPM
Saipem
BIT
BAMI
Banco BPM
BIT
PRY
Prysmian
BIT
BPE
Bper Banca
BIT
TITR
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network